RiverVest Venture Partners
Venture capitalSt. Louis · Pre-Seed–Late Stage · 23 people tracked
Also known as RiverVest Venture · RIVERVEST VENTURE MANAGEMENT LLC
Investment thesis
RiverVest focuses on building life sciences companies, aiming to improve patient outcomes by backing innovation in biotechnology, pharmaceuticals, and medical technology. The firm supports entrepreneurs through a combination of scientific insight, strategic guidance, and operational involvement, and seeks to earn the trust of its investors. Its portfolio spans therapeutics areas such as neurodegenerative disease, rare liver diseases, and metabolic conditions like difficult-to-control type 2 diabetes, reflecting a deep-science approach to venture creation.
Source: firm website, verified Aug 25, 2026.
Team · 23 people
from the firm's website & public directories
What they invest in
from 46 of 69 portfolio companiesBiotech ×35Healthtech ×26Medical Devices ×19Digital Health ×7Hardware ×2SaaS ×2AdTech ×1AgTech ×1
HQs:United States×34Mexico×1Vietnam×1
Who they back
founder profiles across 14 portfolio companiesFounding team size:solo founder×122 founders×2
Investments · 69 tracked
founders shown can be your intro pathBy year:2026 · 12025 · 52024 · 12023 · 32021 · 32020 · 12019 · 12018 · 12017 · 22015 · 22014 · 222 dated
Spruce Biosciences develops and commercializes therapies for serious neurological and endocrine disorders with unmet medical need, with a lead investigational enzyme replacement therapy (TA-ERT) for Mucopolysaccharidosis Type IIIB (Sanfilippo Syndrome Type B).
BiotechHealthtechSouth San Francisco, US
Javier Szwarcberg(Executive Officer, Director)Samir Gharib(Executive Officer)RICHARD KING(Executive Officer, Director)
BoardSimpson Camilla(Director)Tiba Aynechi(Director)inBali Muralidhar(Director)in
Board seatNiall O'Donnell· per SEC Form D
Co-investorsAisling CapitalHealthCapAbingworthNorwest Venture PartnersOrbiMed
Avalyn Pharma develops inhaled therapies for pulmonary fibrosis, using a nebulization approach that delivers treatment directly to the lungs to reduce the tolerability problems of existing oral therapies.
BiotechHealthtech
Lyn Baranowski(CEO)in
Co-investorsAndera PartnersCatalio Capital Management, LPF-Prime CapitalInVivium CapitalNorwest Venture PartnersSR One Capital Management+7 more
MacroGenics is a clinical-stage biopharmaceutical company developing antibody-based therapies for cancer patients.
BiotechHealthtechMedical Devices
Co-investorsHavencrest Capital ManagementRidgeback CapitalSanofi Ventures
Mirum Pharmaceuticals is a biopharmaceutical company that develops and delivers therapies for people living with rare diseases.
BiotechHealthtechSan Diego, US
Chris Peetz(Co-founder & Chief Executive Officer)inChristopher Peetz(Executive Officer, Director)Eric Bjerkholt(Executive Officer)Peter Radovich(Executive Officer)
BoardPatrick Heron(Director)Michael Grey(Director)
Co-investorsChiesi VenturesFrazier Life SciencesNew Enterprise Associates (NEA)Norwest Venture Partners
OnKure Therapeutics is a clinical-stage biopharmaceutical company developing PI3Kα pan-mutant selective inhibitor medicines for the treatment of breast cancer and vascular anomalies.
BiotechDigital HealthHealthtechMedical DevicesBoulder, US
Jason Leverone(Executive Officer)Samuel Agresta(Executive Officer)Dylan Hartley(Executive Officer)Nicholas Saccomano(Executive Officer, Director)Wendy Johnson(Executive Officer)
BoardIsaac Manke(Director)in
Co-investorsAccess BiotechnologyAbingworthACORN BIOVENTURESBoulder VenturesNew Enterprise Associates (NEA)
Xilio Therapeutics is a clinical-stage biotechnology company developing masked immuno-oncology therapies that use protein engineering to remain inactive until activated by tumor-specific proteases within the tumor microenvironment.
BiotechHealthtechWaltham, US
Rene Russo(Executive Officer, Director)inJoseph Farmer(Executive Officer)Timothy Clackson(Executive Officer)Paul Clancy(Director)Daniel Curran(Director)Nancy Hong(Director)
Co-investorsBain Capital Life SciencesBay City CapitalF-Prime CapitalM VenturesMRL Ventures FundRA Capital+4 more
Engrail Therapeutics is a clinical-stage pharmaceutical company developing precision-targeted therapeutics for neupropsychiatric and neurodevelopmental disorders.
BiotechDigital HealthMedical DevicesSan Diego, US
Stephen(Co-founder, EVP Research & Development and Chief Development Officer)Paul Cayer(Chief Financial Officer)Vikram(President and Chief Executive Officer)Kimberly(Chief Scientific Officer)Quentin(Chief Technical Officer)
Co-investorsForesite CapitalLongwood FundNorwest Venture PartnersYsios Capitalabrdn plcEight Roads Ventures+4 more
Alleviant Medical develops an investigational minimally invasive medical device using interatrial shunt therapy to treat heart failure patients, currently in FDA-approved clinical trials (ALLAY-HF and ALLAY-HFrEF).
BiotechHealthtechMedical DevicesAustin, US
Adam Berman(Executive Officer, Director)Jacob Kriegel(Executive Officer, Director)Avni Patel(Executive Officer, Director)Christopher Alex Arevalos(Executive Officer, Director)Albertien Greijdanus(Executive Officer, Director)
BoardGeoff Pardo(Director)
Board seatJay W. Schmelter· per SEC Form D
Co-investorsBroadview VenturesTMC Venture FundCadence Healthcare VenturesGilde HealthcareGilmartin Capital LLCS3 Ventures+1 more
Bonum Therapeutics develops antibody-controlled protein therapeutics that remain inactive until bound to their target, using a sensor-domain mechanism to deliver regulated, targeted activity.
BiotechHealthtechSeattle, US
John Mulligan(Executive Officer, Director, Promoter)inNeela Patel(Executive Officer)inDiane Hollenbaugh(Executive Officer)in
BoardSamuel Bjork(Director)inMonique Schiersing(Director)in
Board seatJohn McKearn· per SEC Form D
Co-investorsRoche Venture FundVivo Capital3x5 PartnersCodon CapitalDigitalis Ventures
HealthtechSt. Louis, US
Igor R. Efimov(Director)M. Brent Shelton(Executive Officer)Paula Skjefte(Executive Officer, Director)Nick Lanners(Executive Officer)Igor Efimov(Director)
BoardEric A. Gulve(Executive Officer, Director)
Board seatJay W. Schmelter· per SEC Form D
Acquired by Horizon Therapeutics in 2020.
BiotechSan Diego, US
Mike Grey(Executive Officer, Director)Susan Dube(Executive Officer)
BoardKyle Rasbach(Director)Johan Kordel(Director)Ed Mathers(Director)in
Board seatNiall O'Donnell· per SEC Form D
Co-investorsNew Enterprise Associates (NEA)
Avalyn Pharma (formerly Genoa Pharmaceuticals) is a biopharma company developing inhaled therapies for idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases.
BiotechHealthtechSan Diego, US
Mark W. Surber, Ph.D.(Executive Officer, Director)Richard G. Vincent(Executive Officer)
BoardMichael J. Kamdar(Director)Daniel D. Burgess(Director)
Board seatNiall O'Donnell· per SEC Form D · $189.2M raise · filed Oct 2023
Co-investorsNorwest Venture PartnersSofinnova Ventures
InterVene, Inc. is a medical device company that has developed a fully integrated mechanical thrombectomy system to treat venous in-stent restenosis and residual thrombotic venous obstructions and occlusions.
BiotechHealthtechMedical DevicesMountain View, US
Fletcher Wilson(Executive Officer, Director)
BoardThomas Fogarty(Director)Mel Schatz(Director)
Board seatJay W. Schmelter· per SEC Form D
Co-investorsLaunchCapitalTreo Ventures, LlcEmergent Medical Partners, LLP
BiotechSouth San Francisco, US
David Wurtman(Executive Officer, Director)M. Scott Harris(Executive Officer)
BoardJason Hong(Director)Casey Cunningham(Director)Sanford Zweifach(Director)
Board seatNiall O'Donnell· per SEC Form D · $33.9M raise · filed Apr 2017
Clinical-stage immuno-oncology company developing antibodies derived from the immune systems of 'Elite' cancer responders.
BiotechHouston, US
Alice Bexon(Executive Officer)Clifford J. Stocks(Director, Executive Officer)Kamal D. Puri(Executive Officer)Chris Russell(Executive Officer)Russ Hawkinson(Executive Officer)
BoardSteven Gillis(Director)in
Board seatJohn McKearn· per SEC Form D
Co-investors3B Future Health FundCanaan PartnersGreatPoint VenturesARCH Venture PartnersBering CapitalIntervest+3 more
EnergyOakland, US
James C David(Executive Officer, Director)Woody Gibson(Executive Officer)Stewart Ramsay(Executive Officer, Director)
BoardAnthony Arnerich(Director)Jay Schmelter(Director)inTony Arnerich(Director)
Board seatJay W. Schmelter· per SEC Form D · $85.8M raise · filed Jan 2020
Co-investorsEnergy Transition Ventures3x5 Partners
Sparrow Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted therapies for cardiometabolic disease.
BiotechHealthtechMedical DevicesPortland, US
Robert Jacks(Executive Officer, Director)David Aaron Katz(Executive Officer, Director)
BoardJonathan Root(Director)inZach Scheiner(Director)inKlaus Veitinger(Director)in
Board seatNiall O'Donnell· per SEC Form D
Co-investorsOrbiMedRA CapitalUS Venture Partners
Durham, US
AARON V. KAPLAN(Director)SHAWN MCCARTHY(Director)Alejandro Sanchez(Director)Shawn P. McCarthy(Executive Officer, Director)Brett Farabaugh(Executive Officer)Aaron V. Kaplan(Director)
Board seatJay W. Schmelter· per SEC Form D · $8M raise · filed Feb 2017
BiotechSaint Louis, US
Kalthleen L. Beckmann(Executive Officer)Robert W. Karr(Executive Officer, Director)Pamela Manning(Executive Officer)William Frazier(Director)
BoardCharles Bolten(Director)
Board seatJohn T. McKearnJohn McKearn· per SEC Form D · $86.3M raise · filed Aug 2016
HealthtechPlymouth, US
John Pigott(Executive Officer, Director)Jenny Zeroni(Executive Officer)Dave Michaelson(Executive Officer)Kathy Leith(Executive Officer)Jill Schweiger(Executive Officer)Shelby Hautman(Executive Officer)
Board seatKaren Spilizewski· per SEC Form D
Co-investorsEndeavour VisionS3 Ventures
Allotera (formerly Wugen) develops allogeneic T-cell therapies.
BiotechHealthtechMedical DevicesSt. Louis, US
Ayman Kabakibi(Executive Officer)Cherry Thomas(Executive Officer)Kumar Srinivasan(Executive Officer, Director)Keith Vendola(Executive Officer)Daniel M Kemp(Executive Officer, Director)Matthew Cooper(Executive Officer)
Board seatNiall O'DonnellJohn McKearn· per SEC Form D
Co-investorsAisling CapitalAlpha Wave GlobalBioGenerator VenturesAbingworthFidelity InvestmentsIntermediate Capital Group+1 more
Co-investorsAccess Venture PartnersAdit Ventures Management, LlcAgilitas Private EquityAlba Infra PartnersALIVE Israel HealthTech FundAlkemi Growth Capital+73 more
Portfolio company that completed a successful 2018 biotech IPO, resulting in a 9x return for RiverVest.
BiotechSan Carlos, US
Nenad Tomasevic(Executive Officer)Christopher Bebbington(Executive Officer, Director)Alejandro Dorenbaum(Executive Officer)
BoardFarah Champsi(Director)inJohn McKearn(Director)inPeter Moldt(Director)
Co-investorsAlta PartnersNew Enterprise Associates (NEA)Samsara BioCapitalRoche Venture Fund
Co-investorsAisling CapitalLYZZ Capital
Developing broad-spectrum antifungal agents for invasive fungal infections.
BiotechSan Diego, US
Mitchell Mutz(Executive Officer, Director)
BoardChrysa Mineo(Director)Jack Florio(Director)Elaine Heron(Director)Santosh Vetticaden(Director)Karen Talmadge(Director)
Co-investorsNew Enterprise Associates (NEA)Pappas CapitalSofinnova VenturesSofinnova Venture Partners
Pfizer discovers, develops, manufactures, and distributes pharmaceutical medicines and vaccines across therapeutic areas including oncology, cardiology, immunology, and infectious diseases.
BiotechHealthtechMedical DevicesNew York, US
Charles Pfizer
Co-investorsAisling CapitalAndera PartnersRho Capital PartnersRho VenturesVenrockNew Enterprise Associates (NEA)
Co-investorsAvego BioScience CapitalBioGenerator VenturesPerot Jain
Atalanta develops RNA interference-based therapeutics aimed at treating central nervous system and neurological diseases.
BiotechHealthtech
Co-investorsF-Prime CapitalNovartis Venture FundSanofi Venturesabrdn plcEQT Life Sciences
Biogen is a biotechnology company founded in 1978 that focuses on breakthroughs in biology.
BiotechMedical Devices
Co-investorsAlpha Wave GlobalAsset Management Company
Biolinq develops the Shine sensor, a needle-free glucose monitor that measures glucose along with physical activity and sleep in a single wearable device.
Digital HealthHardwareMedical Devices
Jared Tangney(Founder)inRich Yangin
Co-investorsAble PartnersAlpha Wave GlobalAphelion CapitalAverin CapitalBOLD LongevityHikma Ventures+2 more
Biolinq develops a non-invasive glucose sensor that uses light to display glucose levels in real time, while also tracking activity and sleep to provide personalized health insights via a mobile app.
BiotechDigital HealthHealthtechMedical DevicesSan Diego, US
Jared Tangney(Executive Officer, Director, Promoter)inRichard Yang(Executive Officer, Director)Edward Kliphuis(Director)
BoardDaniel Bradbury(Director)inLana Ghanem(Director)
Co-investorsAlpha Wave GlobalBeyond CapitalBioBritJDRF T1D FundAphelion CapitalHikma Ventures+1 more
Healthcare company acquired by Mirum Pharmaceuticals, a former RiverVest portfolio company.
San Mateo, US
Keting Chu(Executive Officer, Director)Dajun Yang(Director)Nancy Hong(Director)Alon Lazarus(Director)William J. Rutter(Director)Ting Jia(Director)
Co-investorsFrazier Life SciencesRA CapitalHBM Healthcare InvestmentsNovo HoldingsT. Rowe PriceWellington Management
Portfolio company acquired by Pharmion, delivering a 6x return.
Lifepoint is a diversified healthcare delivery network operating community hospitals, rehabilitation and behavioral health hospitals, and additional sites of care across the healthcare continuum.
Digital HealthHealthtech
Scott Mercy(Founding Chairman and CEO)
Gilead discovers, develops, and delivers innovative therapeutics for people with life-threatening diseases, focusing on virology, oncology, and inflammation across more than 35 countries.
BiotechDigital HealthHealthtechMedical DevicesFoster City, US
Lou Lange(Founder)Michael L. Riordan(Founder)inDaniel O'Dayin
Co-investorsAisling CapitalAsset Management CompanyFrazier Life SciencesKleiner PerkinsLongitude CapitalLumira Ventures+5 more
Captisol is a pharmaceutical-grade sulfobutylether beta-cyclodextrin (SBECD), a derivatized beta cyclodextrin used to solubilize and stabilize difficult-to-deliver molecules across routes such as parenteral, oral, ophthalmic, nasal, and inhalation.
BiotechHealthtechNew Materials
Medtronic designs and develops medical technology for treating complex diseases.
AI & Machine LearningDigital HealthHealthtechMedical Devices
Co-investors8VCCWRU Technology VenturesElevate VenturesMenlo VenturesOak Investment PartnersPfizer Venture Investments+5 more
Bristol Myers Squibb is a biopharmaceutical company that develops and delivers medicines across oncology, hematology, neuroscience, immunology, and cardiovascular disease areas.
BiotechHealthtechMedical DevicesNew York, US
Co-investorsKleiner PerkinsNew Enterprise Associates (NEA)Nextech InvestProspect Venture PartnersRho Capital PartnersRho Ventures+2 more
Developing therapies for congenital disorders of glycosylation combining replacement therapies with intracellular delivery vehicles.
BiotechSan Francisco, US
Christopher Starr(Director)Peter C.M. McWilliams(Director)Agnes Rafalko(Executive Officer, Director)
BoardGiacomo Chiesi(Director)
Co-investorsAdvent Life SciencesChiesi VenturesCTI Life Sciences Fund L.P.Remiges Ventures, Inc.Sanderling VenturesSanofi Ventures
Glycomine develops therapeutics for rare diseases, many of which currently lack disease-modifying treatment options.
Biotech
Steven Axon(Chief Executive Officer)Hicham Alaoui(Chief Scientific Officer)Rose Marino(Chief Medical Officer)Peter McWilliams(Chief Business Officer)Geoffrey Hird(Chief Technology Officer)
Co-investorsAdvent Life SciencesMission Bay CapitalMission BiocapitalRemiges Ventures, Inc.Sanderling VenturesSanofi Ventures
Portfolio company acquired by Roche.
BiotechSeattle, US
John Mulligan(Executive Officer, Director, Promoter)Mitchell Mutz(Director)Nicholas Walrod(Director)
BoardJohn McKearn(Director)inKarl Handelsman(Director)
Co-investorsDigitalis VenturesRoche Venture Fund
RiverVest portfolio company where Andrew Kleiboeker holds a board observer seat.
Acquired by Shire in 2014 (now part of Takeda).
BiotechMedical Devices
Co-investorsFrazier Life SciencesLongitude CapitalOberland Capital
Company founded by RiverVest that exited with an 8.0x gross return.
Maxwell Biomedical develops a device-based alternative to catheter ablation for atrial fibrillation, using closed-loop adaptive left atrial multisite pacing and Spatial Resynchronization Therapy (SRT) to terminate AF without high-energy shock.
BiotechHardwareHealthtechMedical Devices
Randy Werneth(CEO, President)Timothy Corvi(Sr. VP, R&D)Derrick Chou(VP, Science & Technology)
Co-investorsBroadview Ventures
Neuros Medical develops the Altius Direct Electrical Nerve Stimulation System, an FDA-approved implantable device that delivers patient-controlled electrical stimulation to treat chronic post-amputation pain in adult lower limb amputees.
BiotechHealthtechMedical DevicesAliso Viejo, US
David Veino(President and CEO)Zach Stassen(Chief Financial Officer)Robert J. Centa(Chief Financial Officer)Jon J. Snyder(Director, President, Secretary and CEO)
BoardJoyce Erony(Director)inWilliam Harrington(Director)
Co-investorsAmzak HealthAPERTURE Venture PartnersCWRU Technology VenturesiSelect FundJobsOhio VenturesJumpstart Ventures+5 more
Xoilac TV is a free online football (soccer) live-streaming platform serving fans in Vietnam, offering Full HD match broadcasts of European, Asian, Vietnamese, and international competitions.
ConsumerMedia & EntertainmentSports Tech
Co-investorsAisling CapitalNew Enterprise Associates (NEA)AbingworthLundbeckfonden VenturesPappas Capital
Medical device company co-founded by Jay Schmelter; one of RiverVest's first two investments.
Scout Bio developed biotechnology therapies for pets, including a pipeline of monoclonal antibodies and gene therapy programs targeting chronic diseases in companion animals.
AgTechBiotechDeep TechHealthtechPhiladelphia, US
Mark Hefferman(Executive Officer, Director)
BoardAditya Kohli(Director)inTadataka Yamada(Director)Patrick Heron(Director)inCindy Cole(Director)inNancy Hong(Director)
Co-investorsCompanion FundDigitalis VenturesFrazier Life Sciences
BiotechWaltham, US
Ellen E. Sheets(Executive Officer, Director)
BoardCarl M. Berke(Director)Nancy Hong(Director)
Co-investorsBold Capital PartnersDigitalis VenturesKdT Ventures
ShareFile provides secure file sharing, document collection, e-signature capabilities, and automated workflow management for teams collaborating with clients, partners, and vendors.
Enterprise SoftwareSaaS
Co-investorsAstellaBlack Diamond VenturesBrightstone Venture CapitalCID CapitalConcord Health PartnersH Venture Partners+1 more
Standard Bariatrics develops the Titan SGS™ Stapler, a specialized surgical device designed for sleeve gastrectomy procedures that creates consistent and symmetrical gastric pouches using an anatomy-based approach.
Medical Devices
Co-investorsCincyTechEmergent Medical Partners, LLPHatteras Venture PartnersJobsOhio VenturesRC CapitalUS Venture Partners
Statcounter provides website analytics and visitor tracking software that displays traffic data, user behavior, and engagement metrics in a simple interface.
AdTechData & InfrastructureMarketing TechSaaS
Aodhán Cullen(Founder and CEO)
Co-investorsGabriel Venture PartnersHomegrown CapitalHuangpu River CapitalIaso VenturesKumpulan Modal PerdanaNucleation Capital+2 more
BiotechCoppell, US
Alvaro F. Guillem(Executive Officer, Director)Todd Creech(Executive Officer)Donald Jeffrey Keyser(Executive Officer, Director)Cynthia Smith(Executive Officer)Henrick Sandvad Rasmussen(Executive Officer)Robert Alexander(Executive Officer, Director)
Co-investorsSofinnova Ventures
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 11
IPOs and acquisitions across the tracked portfolioSpruce BiosciencesNASDAQ: SPRBAvalyn Pharma IncNASDAQ: AVLNMacrogenics IncNASDAQ: MGNXMirum PharmaceuticalsNASDAQ: MIRMOnkure Therapeutics IncNASDAQ: OKURXilio TherapeuticsNASDAQ: XLOCurzion Pharmaceuticals Incacq. by Horizon TherapeuticsCabrellisacq. by PharmionGood Therapeuticsacq. by RocheLumena Pharmaceuticalsacq. by ShireScout Bio Incacq. by Ceva Santé Animale
Portfolio news
latest coverage across their companiesXilio Therapeutics · tickerreport.com · Aug 15, 2026
Spruce Biosciences · stocktitan.net · Aug 14, 2026
Mirum Pharmaceuticals · finance.yahoo.com · Aug 13, 2026
Wugen · bizjournals.com · Jul 10, 2026
Avalyn Pharma Inc · investing.com · May 1, 2026
Anacor · sif.gatesfoundation.org · Feb 3, 2026
VentureMed Group · finsmes.com · Oct 29, 2025
Biolinq · fiercebiotech.com · Sep 29, 2025
Frequently asked questions
- How many investments has RiverVest Venture Partners made?
- RiverVest Venture Partners has 62 tracked investments, 5 of which have exited via acquisition or IPO, including 5 dated in the last 24 months.
- What stage does RiverVest Venture Partners invest at?
- RiverVest Venture Partners invests at the Pre-Seed, Seed, Series A, Series B, Series C, Growth, Late Stage stages.
- What is RiverVest Venture Partners's typical check size?
- RiverVest Venture Partners typically writes checks of $500K – $3M.
- What sectors does RiverVest Venture Partners focus on?
- RiverVest Venture Partners focuses on Biotech, Digital Health, Healthtech, Medical Devices.
- Where is RiverVest Venture Partners located?
- RiverVest Venture Partners is headquartered in St. Louis, US.
- Does RiverVest Venture Partners lead rounds?
- Yes, RiverVest Venture Partners leads investment rounds.
- Who does RiverVest Venture Partners co-invest with?
- RiverVest Venture Partners most often shares deals with New Enterprise Associates (NEA), Aisling Capital, Frazier Life Sciences, among 122 tracked co-investors.
Media · Podcasts & interviews
featuring the teamTom Melzer, Managing Director & Co-Founder, RiverVest Venture Partners
InvestMidwest Venture Capital (Forum) · Tom Melzer
Co-investors · 21
New Enterprise Associates (NEA) is a venture capital firm that invests in and provides long-term support to founders building new companies.
F-Prime Capital is an early-stage-focused investment firm backing companies across life sciences, technology, healthtech and services, and crypto.
Sanofi Ventures is the corporate venture capital arm of Sanofi, investing in early-stage biotech and digital health companies focused on improving human health. It serves as Sanofi's entry point into the innovation ecosystem.
Abingworth is a life science venture capital firm that backs early-stage biopharma and biotech companies, helping entrepreneurs translate scientific discoveries into new therapeutics.
Digitalis Ventures invests in solutions to unmet needs in biomedicine and health, backing biotechnology and technology-enabled companies across human health and animal health.
Roche Venture Fund is a corporate venture arm that invests in early-stage biotech and diagnostics companies across more than 10 countries, with a portfolio exceeding 30 portfolio companies. The fund is headquartered in Basel, Switzerland.
OrbiMed is a global healthcare-focused investment firm providing financing and operational support to companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.
S3 Ventures is a venture capital firm founded in 2005 that invests in technology companies and medical device/health software startups, backed by a single philanthropic limited partner.
Pivotal Life Sciences is an investment platform focused on funding innovative companies developing therapeutic products and technologies aimed at major unmet medical needs.
Advent Life Sciences is a trans-Atlantic venture capital firm investing in early and mid-stage life sciences companies across the UK, Europe and the USA.
Canaan Partners is a venture capital firm with over 30 years of history, backing companies across technology and healthcare sectors through close, hands-on partnerships with founders.
SR One is a biotechnology-focused venture capital firm that partners with founders to develop innovative science into new medicines.
▶9 more co-investors
ForbionAlta PartnersCodon CapitalUnknown VenturesPolaris PartnersOUP (Osage University Partners)Deerfield Management CompanyDomain AssociatesFrazier Healthcare Partners
Firms observed investing alongside RiverVest Venture Partners, from public investor directories. Shared companies are the overlap with RiverVest Venture Partners's recorded portfolio.
Similar investors
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.
Khosla Ventures is a venture capital firm that invests in early-stage companies focused on technology, mobile, and clean energy sectors, including biotechnology applications. The firm provides capital and strategic support to entrepreneurs developing breakthrough technologies across multiple markets.
Pontifax is an investment firm focused on life sciences and healthcare technologies, backing companies across all development stages from early research to clinical-stage growth.
Accelmed Partners is a healthcare technology investment firm that applies a private equity approach to a sector traditionally served by venture and early-stage growth investors, focusing on tools & diagnostics, digital health, and tech-enabled services.